Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Spasticity, Post-stroke | Do not list | Complete | ||
Xermelo | telotristat | carcinoid syndrome | Do not reimburse | Complete | ||
Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from breast cancer | List with clinical criteria and/or conditions | Complete | ||
XGEVA | Denosumab | Prevention of skeletal-related events due to bone metastases from solid tumours | List with clinical criteria and/or conditions | Complete | ||
Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer | List with clinical criteria and/or conditions | Complete | ||
Xiaflex | Collagenase clostridium histolyticum | Dupuytren’s contracture | List with criteria/condition | Complete | ||
XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | |||
Xolair | omalizumab | Chronic rhinosinusitis with nasal polyps | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Xolair | Omalizumab | Chronic idiopathic urticaria | List with clinical criteria and/or conditions | Complete |